The World Economic Forum (WEF) and the Harvard School of Public Health report entitled “The Global Economic Burden of Non-communicable Diseases” estimates global diseases kill 36 million people every year and will cost upwards of US$47 trillion by 2030.


The World Health Organization's four biggest killers; cancer, heart disease, diabetes and chronic respiratory disease are dominant in non-communicable disease (NCD) mortality and morbidity. All four are increasing in prevalence  and the cost of treatment is spiraling out of control.


Exactly what is Diabetes?

Diabetes is a condition in which blood sugar levels are too high.


Much of the food you eat is broken down into a simple sugar called glucose. In response to a rise in glucose levels after a meal the islets beta-cells in the pancreas read blood glucose  levels and secrete insulin into the blood. Insulin acts to open the gates of cells allowing the glucose to move from the blood stream into the cells where it can be utilized for energy.

A Type 1 diabetes diagnosis means the pancreatic beta cells that read glucose levels and secrete insulin have been damaged or destroyed. Thus glucose cannot move from the bloodstream into the cells.

A Type 2 (insulin resistance) diabetes diagnosis is a far more common verdict for people than Type 1. Insulin resistance happens because of chronically elevated blood sugar and insulin levels.

These elevated levels of sugar and insulin have the effect of "numbing" the cellular processes which move the sugar from the blood stream to the cells - the body cannot respond to the insulin "requests" to move blood sugar into the cells. Roughly 27% of the people who start out as Type 2 diabetics, will, in the future require insulin injections similar to Type 1 diabetics.


Between Type-1 and Type-2 patients with diabetes the total number of diabetics requiring insulin in just North America, is about nine million.


Sernova Corp. TSX:V-SVA is a Canadian-based medical device development company focused on chronic metabolic, neurological, and haematological diseases. Due to the enormous market and potential for significantly improved patient treatment, Sernova’s first product focus is on diabetes.


Sernova’s Cell Pouch System™ is a versatile, scalable credit card-sized device, made of FDA approved materials that provides a natural "organ-like" environment for therapeutic cells such as insulin producing islets for diabetics. Think of the Cell Pouch System™ as a potential natural insulin producing pump with the added benefit of fine-tuned glucose control. Placed under the skin in a simple inexpensive procedure it develops endocrine pancreas like characteristics when islets are placed into the device taking over normal glucose control. A key feature of the device is its ability to stimulate natural microvessel development, thought to be essential for long-term survival and function of therapeutic cells.



Latest News Release

Advances Made in Cell Pouch(Tm) Clinical Development and Positive Outlook for Company’s New Therapeutic Cell Technologies

November 10th, 2014, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire – November 10th, 2014) - Sernova Corp. (TSX-V: SVA), a clinical stage company developing cell therapy technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and hemophilia, today provides a corporate update, summarizing advances made in the clinical development of its Cell Pouch(TM) over the past 12 months and the application of its technologies to new disease indications.

Cell Pouch(TM) Clinical Initiatives

The clinical assessment of the Cell Pouch(TM) in brittle diabetic patients with hypoglycemia unawareness who have received an islet transplant has shown in a small cohort of patients in interim analysis that the Cell Pouch(TM) is biocompatible and safe following implant and transplant. Safety is the primary endpoint of the study.

Initial data from the study have shown the following three important findings:

  • First, biocompatibility and a positive safety profile of the Cell Pouch(TM) have been shown in the first cohort of patients.

  • Second, the islets within the Cell Pouch(TM), as shown by histological analysis, are well-vascularized, living within a natural tissue matrix and are able to make insulin, glucagon and somatostatin, key hormones in the control of blood glucose levels. We believe such revascularization of islets and islet metabolic function within an implantable medical device for therapeutic cells in humans in this patient population is a first in the regenerative medicine field.

  • Third, these positive developments of the study suggest that Sernova’s Cell Pouch(TM) may form a suitable environment for the survival and function of multiple types of therapeutic cells including human stem cells which can represent a virtually unlimited supply of cells for treating disease.

“Sernova has achieved a major milestone with its first-in-human testing”, remarked Dr. James Shapiro, Principal Investigator for the diabetes study.  “Our respective scientific teams are moving ahead to accelerate the pace of innovation, and believe the Cell Pouch(TM) is a highly promising vehicle for transplantation of future stem cell therapies”.

With the encouraging pre-clinical and interim clinical results, Sernova maintains its longer term strategy and objective to achieve a complete solution for treatment of insulin-dependent diabetes, including access to an unlimited supply of insulin producing tissue such as that developed from stem cell technologies, and protection from immune system attack using local immune protection technologies within the pre-vascularized Cell Pouch(TM).

Research and Development Collaboration with Dr. Shapiro

In an independent pre-clinical study, it has been shown that the Cell Pouch(TM) provided insulin independence for 100 days in a small animal model of diabetes using a marginal (minimal) transplanted islet mass. The encouraging results of this study will be released in more detail upon acceptance for publication in a peer reviewed medical journal.

Hemophilia Collaboration with Medicyte GmbH

The research and development teams at Medicyte and Sernova are continuing to work closely in the development of a product to treat Hemophilia A patients. This product involves taking a small blood sample from the patient, correcting the genetic defect in isolated cells and then using Medicyte’s upcyte® technology to expand the cell numbers for placement into the Cell Pouch(TM) for release of Factor VIII. The teams are currently conducting proof of concept studies which include cell isolation, processing and scale-up, product release and preclinical evaluation. Once these studies are successfully completed, the next steps will include GMP manufacturing of the cells and formal pre-clinical studies in preparation for human clinical trials.

New Cell Pouch(TM) Clinical Indications for Metabolic Disorders

As the Company continues its work on the diabetes and hemophilia indications, we are pursuing new autograft (self-cell) and/or allograft (donor-cell) clinical indications with academic and corporate collaborators to further expand the application of its cell therapy platform technologies. We plan to announce these further applications as new development agreements are signed.

Patent Developments

A strong patent portfolio covering the Company’s cell therapy technologies is an essential part of our business and an important element for attracting large pharma development partners.  As such, we have put resources into developing our international patent portfolio and continue to be successful with the ongoing process of international patent prosecution involving the Company’s medical device, therapeutic cell and local immune protection technologies. We currently have achieved 25 issued patents and 27 pending patents in 9 patent families.

Development of Strategic Business Partnerships

As part of our partnering and licensing strategy, Sernova has hired a business development team with extensive experience with in-licensing technologies and developing corporate partnerships with emerging and large pharma/medical device companies. These activities broaden the company’s technology base, validate our technologies, and may provide additional funding sources and expertise to advance our clinical programs to product approval. In this regard, we are in business discussions with a number of companies with complementary technologies which we expect to result in collaborations to develop new products.

“With its GMP manufactured product, years of strong pre-clinical results and encouraging clinical safety, Sernova’s Cell Pouch(TM) is becoming recognized as an elegant delivery module. We are expanding our relationships with a number of therapeutic cell companies who have interest in their ‘therapeutic cell payload’ being paired with our technologies,” remarked Kevin Egan, Chair of Sernova’s business advisory board. “The pharmaceutical companies we are in discussions with see the Cell Pouch(TM) in conjunction with our local immune protected cell-based technologies as the total regenerative medicine package to treat serious chronic diseases.”

Grant Funding

The Company has applied for and continues to seek non-dilutive sources of funding in the form of government and non-profit society grants which can result in funding for the Company’s ongoing and new research and development programs to support our treasury. The Company has to date secured over $1.0 million in such grants.

Selected Highlighted Corporate Developments

Following are highlights of significant recent developments at Sernova:

  • Released positive interim results from our human clinical trial of the Cell Pouch(TM) with insulin producing islets for the treatment of Type I diabetes, demonstrating tissue biocompatibility and safety for up to 6 months, as well as proof of 30 day islet survival within the Cell Pouch™ following islet transplant.

  • Established an agreement with Medicyte GmbH and initiated pre-clinical studies to jointly evaluate the use of Medicyte’s upcyte® cells in Sernova’s Cell Pouch(TM) to treat patients with Hemophilia A disease.

  • Received the first patent allowance for Methods and Devices for Cellular Transplantation from the Australian Patent Office and further allowances in additional jurisdictions.

  • Continued evaluation of our local immune protection technology within the Cell Pouch(TM) for treatment of chronic diseases following receipt of a contribution agreement for up to $254,300 from the National Research Council of Canada for continued research and development.

  • Appointed biopharma entrepreneur and investor Frank Holler to the Board of Directors.

  • Established a world class business development team to establish corporate partners for Sernova’s programs and to expand Sernova’s proprietary technologies through academic and corporate partnerships.

“We are making solid progress on multiple fronts as we continue to develop our platform technologies in the regenerative medicine arena”, stated Dr. Philip Toleikis, Sernova’s President and CEO. “The further success in our international intellectual property patent development, pursuit of stem cell technologies to gain a virtually unlimited supply of cells to treat diabetes, expansion of our research and development programs into new disease indications, and expansion of our management team in business and corporate development all demonstrate our long-term commitment to develop our promising therapeutic cell technologies into products that markedly improve patient outcomes.”

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.  Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary technologies.


For further information contact:

Philip Toleikis, Ph.D., President and CEO
Tel: (604) 961-2939

Ray Matthews & Associates
Ray Matthews
Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6
Tel: (604) 818-7778



Legal Notice / Disclaimer


This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.


Richard Mills has based this document on information obtained from sources he believes to be reliable but which has not been independently verified.


Richard Mills makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Richard Mills only and are subject to change without notice. Richard Mills assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission.


Furthermore, I, Richard Mills, assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.

To contact us please email

Ahead of the Herd